WO2006023778A2 - Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof - Google Patents
Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof Download PDFInfo
- Publication number
- WO2006023778A2 WO2006023778A2 PCT/US2005/029634 US2005029634W WO2006023778A2 WO 2006023778 A2 WO2006023778 A2 WO 2006023778A2 US 2005029634 W US2005029634 W US 2005029634W WO 2006023778 A2 WO2006023778 A2 WO 2006023778A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nmr
- mhz
- ppm
- cocd
- apoptosis
- Prior art date
Links
- 0 C*C(C)CC(C)(*[C@@](C)N)N Chemical compound C*C(C)CC(C)(*[C@@](C)N)N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/10—Polyhydroxy benzenes; Alkylated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
- C07C39/17—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings containing other rings in addition to the six-membered aromatic rings, e.g. cyclohexylphenol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
- C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
- C07C49/83—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/12—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Definitions
- This invention is in the field of medicinal chemistry.
- the invention relates to small molecules which function as inhibitors of anti- apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL).
- the invention also relates to the use of these compounds for inducing apoptotic cell death and sensitizing cells to the induction of apoptotic cell death.
- the aggressive cancer cell phenotype is the result of a variety of genetic and epigenetic alterations leading to deregulation of intracellular signaling pathways (Ponder, Nature 411:336 (2001)).
- the commonality for all cancer cells is their failure to execute an apoptotic program, and lack of appropriate apoptosis due to defects in the normal apoptosis machinery is a hallmark of cancer (Lowe et al., Carcinogenesis 21:485 (2000)).
- IAPs apoptosis proteins
- IAP proteins potently suppress apoptosis induced by a large variety of apoptotic stimuli, including chemotherapeutic agents, radiation, and immunotherapy in cancer cells.
- the second class of central negative regulators is the Bcl-2 family of proteins, as exemplified by two potent anti-apoptotic molecules, Bcl-2 and Bcl-xL proteins (Adams et al, Science 281:1322 (1998); Reed, Adv. Pharmacol 41:501 (1997); Reed et al, J. Cell. Biochem. 60:23 (1996)).
- the Bcl-2 family of proteins now includes both anti-apoptotic molecules such as Bcl-2 and Bcl-xL and pro-apoptotic molecules such as Bax, Bak, Bid, and Bad.
- Bcl-2 and Bcl-xL Therapeutic strategies for targeting the anti-apoptotic Bcl-2 family members, such as Bcl-2 and Bcl-xL, in cancer to restore cancer cell sensitivity and overcome resistance of cancer cells to apoptosis have been extensively reviewed (Adams et al, Science 281:1322 (1998); Reed, Adv. Pharmacol. 41:501 (1997); Reed et al, J. Cell. Biochem. 60:23 (1996)).
- Bcl-2 antisense therapy is in several Phase III clinical trials for the treatment of solid and non-solid tumors.
- Several laboratories are interested in designing small molecule inhibitors of Bcl-2 and Bcl-xL.
- the present invention contemplates that exposure of animals suffering from cancer to therapeutically effective amounts of dmg(s) (e.g., small molecules) that inhibit the function(s) of anti-apoptotic Bcl-2 family members will kill cancer cells or supporting cells outright (those cells whose continued survival is dependent on the overactivity of anti-apoptotic Bcl-2 family members) and/or render such cells as a population more susceptible to the cell death-inducing activity of cancer therapeutic drags or radiation therapies.
- dmg(s) e.g., small molecules
- the present invention contemplates that inhibitors of anti-apoptotic Bcl-2 family members satisfy an unmet need for the treatment of multiple cancer types, either when administered as monotherapy to induce apoptosis in cancer cells dependent on anti-apoptotic Bcl-2 family member function, or when administered in a temporal relationship with other cell death-inducing cancer therapeutic drags or radiation therapies so as to render a greater proportion of the cancer cells or supportive cells susceptible to executing the apoptosis program compared to the corresponding proportion of cells in an animal treated only with the cancer therapeutic drag or radiation therapy alone.
- combination treatment of animals with a therapeutically effective amount of a compound of the present invention and a course of an anticancer agent or radiation produces a greater tumor response and clinical benefit in such animals compared to those treated with the compound or anticancer drugs/radiation alone.
- the compounds lower the apoptotic threshold of all cells that express anti-apoptotic Bcl-2 family members, the proportion of cells that successfully execute the apoptosis program in response to the apoptosis inducing activity of anticancer drags/radiation is increased.
- the compounds of the present invention can be used to allow administration of a lower, and therefore less toxic and more tolerable, dose of an anticancer agent and/or radiation to produce the same tumor response/clinical benefit as the conventional dose of the anticancer agent/radiation alone. Since the doses for all approved anticancer drugs and radiation treatments are known, the present invention contemplates the various combinations of them with the present compounds. Also, since the compounds of the present invention may act at least in part by inhibiting anti-apoptotic Bcl-2 family members, the exposure of cancer cells and supporting cells to therapeutically effective amounts of the compounds should be temporally linked to coincide with the attempts of cells to execute the apoptosis program in response to the anticancer agent or radiation therapy.
- administering the compositions of the present invention in connection with certain temporal relationships provides especially efficacious therapeutic practices.
- the present invention relates to compounds that are useful for inhibiting the activity of anti-apoptotic Bcl-2 family members and increasing the sensitivity of cells to inducers of apoptosis.
- the compounds have formula I:
- E is phenyl or a heteroaromatic group
- X, Y, and Z are independently H, OH, carboxylic acid, amide, sulfonic acid, sulfonamide, sulfinic acid, sulfanamide, aldehyde, phosphoric acid, phosphonamide, alkyl, alkoxy, or aryl, or one of X and Y or Y and Z form a heterocyclic ring, and at least one of X, Y, and Z is OH, carboxylic acid, amide, sulfonic acid, sulfonamide, sulfinic acid, sulfanamide, aldehyde, phosphoric acid, or phosphonamide;
- U and W are independently CO, SO, SO 2 , (CH 2 ) n , S, NH, NHCO, P, PO, or
- n O or 1;
- Q is H, alkyl, alkenyl, alkynyl, or halogen
- Ri and R 2 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, partially saturated heterocycle, heterocycle; NR3R 4 , OR3, SR3, or CR 3 R 4 R 5 , anyone of which may be optionally substituted; and
- R 3 -R 5 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle or form a ring, anyone of which may be optionally substituted.
- At least one of X, Y, and Z is OH.
- the invention relates to compounds represented by Formula I, which are inhibitors of anti-apoptotic Bcl-2 family members.
- the invention relates to the use if the compounds of the invention to induce apoptosis in cells.
- the invention also relates to the use of the compounds of the invention for sensitizing cells to inducers of apoptosis.
- the compounds are useful for the treatment, amelioration, or prevention of disorders responsive to induction of apoptotic cell death, e.g., disorders characterized by dysregulation of apoptosis, including hyperproliferative diseases such as cancer.
- the compounds can be used to treat, ameliorate, or prevent cancer that is characterized by resistance to cancer therapies (e.g., those which are chemoresistant, radiation resistant, hormone resistant, and the like).
- cancer therapies e.g., those which are chemoresistant, radiation resistant, hormone resistant, and the like.
- the compounds can be used to treat hyperproliferative diseases characterized by overexpression of anti-apoptotic Bcl-2 family members.
- the present invention provides pharmaceutical compositions comprising a compound of Formula I in a therapeutically effective amount to induce apoptosis in cells or to sensitize cells to inducers of apoptosis.
- the invention further provides kits comprising a compound of Formula
- kits may optionally contain other therapeutic agents, e.g., anticancer agents, apoptosis modulating agents.
- the invention also provides methods of making compounds of
- Figure 1 shows the binding of TW-37 to Bcl-2 by NMR analysis.
- Figure 2 shows the inhibition of cell growth in cancer cells in response to TW-37.
- Figure 3 shows the inhibition of cell growth in cancer cells in response to several compounds.
- Figure 4 shows the induction of apoptosis in PC-3 cells in response to
- FIG. 5 shows the activation of caspase-3 in PC-3 and PrEC cells in response to TW-37.
- Figure 6 shows the enhancement of cisplatin cytotoxicity by TW-37 in
- FIG. 7 shows the inhibition of tumor growth in mice in response to
- FIG. 8 shows the effect of TW-37, TAXOTERE, and cisplatin on body weight in mice.
- Figure 9 shows the inhibition of tumor growth in mice in response to
- FIG. 10 shows the effect of TW-37 and TAXOTERE alone and in combination on body weight in mice.
- the present invention relates to compounds represented by Formula I, which function as inhibitors of anti-apoptotic Bcl-2 family members.
- these compounds sensitize cells to inducers of apoptosis and, in some instances, themselves induce apoptosis. Therefore, the invention relates to methods of sensitizing cells to inducers of apoptosis and to methods of inducing apoptosis in cells, comprising contacting the cells with a compound of Formula I alone or in combination with an inducer of apoptosis.
- the invention further relates to methods of treating, ameliorating, or preventing disorders in an animal that are responsive to induction of apoptosis comprising administering to the animal a compound of Formula I and an inducer of apoptosis.
- disorders include those characterized by a dysregulation of apoptosis and those characterized by overexpression of anti-apoptotic Bcl-2 family members.
- anti-apoptotic Bcl-2 family members refers to any known member of the Bcl-2 family of proteins which has anti-apoptotic activity, including, but not limited to, Bcl-2, Bcl-xL, McI-I, Al/BFL-1, BOO- DIVA, Bcl-w, Bcl-6, Bcl-8 and Bcl-y.
- anti-apoptotic Bcl-2 family members refers to an elevated level (e.g., aberrant level) of mRNAs encoding for an anti-apoptotic Bcl-2 family member protein(s), and/or to elevated levels of anti-apoptotic Bcl-2 family member protein(s) in cells as compared to similar corresponding non-pathological cells expressing basal levels of mRNAs encoding anti-apoptotic Bcl-2 family member proteins or having basal levels of anti-apoptotic Bcl-2 family member proteins.
- Methods for detecting the levels of mRNAs encoding anti-apoptotic Bcl-2 family member proteins or levels of anti-apoptotic Bcl-2 family member proteins in a cell include, but are not limited to, Western blotting using anti-apoptotic Bcl-2 family member protein antibodies, immunohistochemical methods, and methods of nucleic acid amplification or direct RNA detection.
- Western blotting using anti-apoptotic Bcl-2 family member protein antibodies immunohistochemical methods, and methods of nucleic acid amplification or direct RNA detection.
- As important as the absolute level of anti-apoptotic Bcl-2 family member proteins in cells is to determining that they overexpress anti-apoptotic Bcl-2 family member proteins, so also is the relative level of anti-apoptotic Bcl-2 family member proteins to other pro-apoptotic signaling molecules (e.g.
- pro-apoptotic Bcl-2 family proteins within such cells.
- the pro-apoptotic signaling molecules would be sufficient to cause the cells to execute the apoptosis program and die, said cells would be dependent on the anti-apoptotic Bcl-2 family member proteins for their survival.
- exposure to an inhibiting effective amount of an anti- apoptotic Bcl-2 family member protein inhibitor will be sufficient to cause the cells to execute the apoptosis program and die.
- an anti-apoptotic Bcl-2 family member protein also refers to cells that, due to the relative levels of pro-apoptotic signals and anti- apoptotic signals, undergo apoptosis in response to inhibiting effective amounts of compounds that inhibit the function of anti-apoptotic Bcl-2 family member proteins.
- anticancer agent and “anticancer drug,” as used herein, refer to any therapeutic agents (e.g., chemotherapeutic compounds and/or molecular therapeutic compounds), radiation therapies, or surgical interventions, used in the treatment of hyperproliferative diseases such as cancer (e.g., in mammals).
- therapeutic agents e.g., chemotherapeutic compounds and/or molecular therapeutic compounds
- radiation therapies or surgical interventions, used in the treatment of hyperproliferative diseases such as cancer (e.g., in mammals).
- prodrug refers to a pharmacologically inactive derivative of a parent “drug” molecule that requires biotransformation (e.g., either spontaneous or enzymatic) within the target physiological system to release, or to convert (e.g., enzymatically, mechanically, electromagnetically) the prodrug into the active drug.
- Prodrugs are designed to overcome problems associated with stability, toxicity, lack of specificity, or limited bioavailability.
- Exemplary prodrugs comprise an active drug molecule itself and a chemical masking group (e.g., a group that reversibly suppresses the activity of the drug).
- Some preferred prodrugs are variations or derivatives of compounds that have groups cleavable under metabolic conditions.
- prodrugs become pharmaceutically active in vivo or in vitro when they undergo solvolysis under physiological conditions or undergo enzymatic degradation or other biochemical transformation (e.g., phosphorylation, hydrogenation, dehydrogenation, glycosylation).
- Prodrugs often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism. (See e.g., Bundgard, Design of Prodrugs, pp. 7-9, 21- 24, Elsevier, Amsterdam (1985); and Silverman, The Organic Chemistry of Drug Design and Drug Action, _pp. 352-401, Academic Press, San Diego, CA (1992)).
- Common prodrugs include acid derivatives -such as esters prepared by reaction of parent acids with a suitable alcohol (e.g., a lower alkanol), amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative (e.g., a lower alkylamide).
- a suitable alcohol e.g., a lower alkanol
- amides prepared by reaction of the parent acid compound with an amine e.g., a lower alkylamide
- salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
- acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, sulfonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
- Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is Cu alkyl, and the like.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- W is Cu alkyl, and the like.
- salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate
- salts include anions of the compounds of the present invention compounded with a suitable cation such as Na + , NH 4 + , and NW 4 + (wherein W is a Ci -4 alkyl group), and the like.
- a suitable cation such as Na + , NH 4 + , and NW 4 + (wherein W is a Ci -4 alkyl group), and the like.
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- a therapeutically effective amount refers to that amount of the therapeutic agent sufficient to result in amelioration of one or more symptoms of a disorder, or prevent advancement of a disorder, or cause regression of the disorder.
- a therapeutically effective amount preferably refers to the amount of a therapeutic agent that decreases the rate of tumor growth, decreases tumor mass, decreases the number of metastases, increases time to tumor progression, or increases survival time by at least 5%, preferably at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100%.
- sensitize and “sensitizing,” as used herein, refer to making, through the administration of a first agent (e.g., a compound of Formula I), an animal or a cell within an animal more susceptible, or more responsive, to the biological effects (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, proliferation, invasion, angiogenesis, or apoptosis) of a second agent.
- a first agent e.g., a compound of Formula I
- the biological effects e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, proliferation, invasion, angiogenesis, or apoptosis
- the sensitizing effect of a first agent on a target cell can be measured as the difference in the intended biological effect (e.g., promotion or retardation of an aspect of cellular function including, but not limited to, cell growth, proliferation, invasion, angiogenesis, or apoptosis) observed upon the administration of a second agent with and without administration of the first agent.
- the response of the sensitized cell can be increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 350%, at least 300%, at least 350%, at least 400%, at least 450%, or at least 500% over the response in the absence of the first agent.
- the term "dysregulation of apoptosis,” as used herein, refers to any aberration in the ability of (e.g., predisposition) a cell to undergo cell death via apoptosis.
- Dysregulation of apoptosis is associated with or induced by a variety of conditions, including for example, autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, graft-versus-host disease, myasthenia gravis, or Sjogren's syndrome), chronic inflammatory conditions (e.g., psoriasis, asthma or Crohn's disease), hyperproliferative disorders (e.g., tumors, B cell lymphomas, or T cell lymphomas), viral infections (e.g., herpes, papilloma, or HIV), and other conditions such as osteoarthritis and atherosclerosis. It should be noted that when the dysregulation is induced by or associated with a viral infections
- hyperproliferative disease refers to any condition in which a localized population of proliferating cells in an animal is not governed by the usual limitations of normal growth.
- hyperproliferative disorders include tumors, neoplasms, lymphomas and the like.
- a neoplasm is said to be benign if it does not undergo invasion or metastasis and malignant if it does either of these.
- a "metastatic" cell means that the cell can invade and destroy neighboring body structures.
- Hyperplasia is a form of cell proliferation involving an increase in cell number in a tissue or organ without significant alteration in structure or function.
- Metaplasia is a form of controlled cell growth in which one type of fully differentiated cell substitutes for another type of differentiated cell.
- autoimmune disorder refers to any condition in which an organism produces antibodies or immune cells which recognize the organism's own molecules, cells or tissues.
- Non-limiting examples of autoimmune disorders include autoimmune hemolytic anemia, autoimmune hepatitis, Berger's disease or IgA nephropathy, celiac sprue, chronic fatigue syndrome, Crohn's disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's disease, Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus, multiple sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, vitiligo, and the like.
- neoplastic disease refers to any abnormal growth of cells being either benign (non-cancerous) or malignant (cancerous).
- anti-neoplastic agent refers to any compound that retards the proliferation, growth, or spread of a targeted (e.g., malignant) neoplasm.
- the terms "prevent,” “preventing,” and “prevention,” as used herein, refer to a decrease in the occurrence of pathological cells (e.g., hyperproliferative or neoplastic cells) in an animal.
- the prevention may be complete, e.g., the total absence of pathological cells in a subject.
- the prevention may also be partial, such that the occurrence of pathological cells in a subject is less than that which would have occurred without the present invention.
- apoptosis modulating agents refers to agents which are involved in modulating (e.g., inhibiting, decreasing, increasing, promoting) apoptosis.
- apoptosis modulating agents include proteins which comprise a death domain such as, but not limited to, Fas/CD95, TRAMP, TNF RI, DRl, DR2, DR3, DR4, DR5, DR6, FADD, and RIP.
- Other examples of apoptotic modulating agents include, but are not limited to, TNFo!, Fas ligand, antibodies to Fas/CD95 and other TNF family receptors, TRAIL, antibodies to TRAILRl or TRAILR2, Bcl-2, ⁇ 53, BAX, BAD, Akt, CAD, PB kinase, PPl, and caspase proteins.
- Modulating agents broadly include agonists and antagonists of TNF family receptors and TNF family ligands.
- Apoptosis modulating agents may be soluble or membrane bound (e.g. ligand or receptor).
- Preferred apoptosis modulating agents are inducers of apoptosis, such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a TNFR-I ligand, or TRAIL
- inhibitors of anti-apoptotic Bcl-2 family members of the present invention are compounds having the general Formula I:
- E is phenyl or a heteroaromatic group
- X, Y, and Z are independently H, OH, carboxylic acid, amide, sulfonic acid, sulfonamide, sulfuric acid, sulfinamide, aldehyde, phosphoric acid, phosphonamide, alkyl, alkoxy, or aryl, or one of X and Y or Y and Z form a heterocyclic ring, and at least one of X, Y, and Z is OH, carboxylic acid, amide, sulfonic acid, sulfonamide, sulfinic acid, sulfinamide, aldehyde, phosphoric acid, or phosphonamide;
- U and W are independently CO, SO, SO 2 , (CH 2 ) n , S, NH, NHCO, P, PO, or
- n O or 1 ;
- Q is H, alkyl, alkenyl, alkynyl, or halogen
- Ri and R 2 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, partially saturated heterocycle, heterocycle; NR 3 R 4 , OR 3 , SR 3 , or CR 3 R 4 R 5 , anyone of which may be optionally substituted; and
- R 3 -R 5 are independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycle or form a ring, anyone of which may be optionally substituted.
- At least one of X, Y, and Z is OH.
- Useful alkyl groups include straight-chained or branched CMS alkyl groups, especially methyl, ethyl, propyl, isopropyl, t-butyl, sec-butyl, 3-pentyl, adamantyl, norbornyl, and 3-hexyl groups.
- Useful alkenyl groups include straight-chained or branched C 2- i 8 alkyl groups, especially ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, and hexenyl.
- Useful alkynyl groups are C 2 _i 8 alkynyl groups, especially ethynyl, propynyl, butynyl, and 2-butynyl groups
- Useful cycloalkyl groups are C 3 . 8 cycloalkyl.
- Typical cycloalkyl groups include cyclopropyl, cyclobufyl, cyclopentyl, cyclohexyl and cycloheptyl.
- Useful aryl groups include C 6 .
- aryl especially phenyl, naphthyl, phenanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups.
- Useful heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalzinyl, naphthyridinyl, quinozalinyl, cinnolinyl, pteridinyl, carbazolyl, ⁇ - carbolinyl,
- heteroaryl group contains a nitrogen atom in a ring
- nitrogen atom may be in the form of an N-oxide, e.g., a pyridyl N- oxide, pyrazinyl N-oxide, pyrimidinyl N-oxide, and the like.
- Optional substituents include one or more alkyl; halo; haloalkyl; cycloalkyl; aryl optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl, aryl, or heteroaryl groups; aryloxy optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl, aryl, or heteroaryl groups; aralkyl; heteroaryl optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl, aryl, or heteroaryl groups; heteroaryloxy optionally substituted with one or more lower alkyl, lower alkoxy, methylenedioxy, halo, haloalkyl, aminosulfonyl,
- Useful amino acid residues include those derived from D and L alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, and histidine.
- Amino acid derivatives include the amide derivatives.
- Useful saturated or partially saturated carbocyclic groups are cycloalkyl groups as defined above, as well as cycloalkenyl groups, such as cyclopentenyl, cycloheptenyl and cyclooctenyl.
- Useful halo or halogen groups include fluorine, chlorine, bromine and iodine.
- Useful alkylaryl and alkylheteroaryl groups include any of the above- mentioned Ci- 1 8 alkyl groups substituted by any of the above-mentioned C ⁇ -w aryl groups or heteroaryl groups.
- Useful values include benzyl, phenethyl and naphthylmethyl.
- Useful haloalkyl groups include Cuio alkyl groups substituted by one or more fluorine, chlorine, bromine or iodine atoms, e.g., fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, chloromethyl, chlorofiuoromethyl and trichloromethyl groups.
- Useful alkoxy groups include oxygen substituted by one of the C MO alkyl groups mentioned above.
- Useful alkylthio groups include sulfur substituted by one of the C MO alkyl groups mentioned above. Also included are the sulfoxides and sulfones of such alkylthio groups.
- Useful amido groups include carbonylamido (i.e., carbonyl bonded to an amino group) as well as any optionally substituted Q.6 acyl (alkanoyl) attached to an amino nitrogen, e.g., acetamido, haloacetamido such as trifluoroacetamido, propionamido, butanoylamido, pentanoylamido, hexanoylamido as well as aryl-substituted C 2 -6 substituted acyl groups.
- Useful acyloxy groups are any C 1 ⁇ acyl (alkanoyl) attached to an oxy
- (— O ⁇ ) group e.g., formyloxy, acetoxy, propionoyloxy, butanoyloxy, pentanoyloxy, hexanoyloxy and the like.
- Useful arylacyloxy groups include any of the aryl groups mentioned above substituted on any of the acyloxy groups mentioned above, e.g., 2,6- dichlorobenzoyloxy, 2,6-difluorobenzoyloxy and 2,6-di-(trifluoromethyl)- benzoyloxy groups.
- Useful amino groups include -NH 2 , -NHRn, and -NRnRn, wherein
- Rn and R 12 are alkyl, aminoalkyl, optionally substituted aryl, optionally substituted arylalkyl, or cycloalkyl groups as defined above or where Rn and R 12 form a C 5 -C O heterocyclic ring such as piperidinyl, pyrrolidinyl, pyrazinyl, or morpholino optionally substituted by a heteroaryl or an acyl group on the nitrogen.
- Useful saturated or partially saturated heterocyclic groups include tetrahydrofuranyl, pyranyl, piperidinyl, piperizinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, indolinyl, isoindolinyl, quinuclidinyl, mo ⁇ holinyl, isochromanyl, chromanyl, pyrazolidinyl, pyrazolinyl, tetronoyl, tetramoyl, or tetrahydroisoquinolinyl groups.
- Certain of the compounds of the present invention may exist as stereoisomers including optical isomers.
- the invention includes all stereoisomers and both the racemic mixtures of such stereoisomers as well as the individual enantiomers that may be separated according to methods that are well known to those of skill in the art.
- the compounds of the present invention have the have formula II, wherein the variables are as defined above and at least one of X, Y, and Z is OH.
- Another embodiment of the invention is compounds having formula
- the compounds of the present invention are of formula IV, wherein the variables are as defined above and at least one of X, Y, and Z is OH.
- the compounds of the present invention are of formula V, wherein the variables are as defined above and at least one of X, Y, and Z is OH.
- reagents and conditions a) Lithium, Grignard, Zinc reagents, etc; b) Et3SiH, TFA; c) ButLi then DMF; d) Lithium, Grignard, Zinc reagents, etc; e) Et 3 SiH, TFA; f) BBr 3 , then MeOH.
- Multi-substituted phenol analogues may be synthesized as shown in
- reagents and conditions a) Lithium, Grignard, Zinc reagents, etc; b) Et 3 SiH, TFA; c) ButLi then DMF; d) Lithium, Grignard, Zinc reagents, etc; e) Dess- Martin Periodinane, DCM; f) BBr 3 , then MeOH.
- reagents and conditions a) 1. Br 2 , AcOH; 2. TsOH, ethylene glycol; b) ButLi then DMF; c) 1. Lithium, Grignard, Zinc reagents, etc; 2. TsOH, acetone; d) Lithium, Grignard, Zinc reagents, etc; e) Dess-Martin Periodinane, DCM; f) BBr 3 , then MeOH.
- the diacyl substituted phenols are prepared from simple aldehydes as shown in Scheme 3.
- methoxybenzaldehyde is brominated regioselectively by bromine in acetic acid.
- the second aldehyde group is introduced by bromine-metal exchange reaction.
- the first alkyl or aryl groups are incorporated into the molecule by addition reaction with one of the aldehyde groups protected.
- the aldehyde protective group is removed in acetone very quickly (longer reaction time will lead to the decomposition of the secondary alcohol).
- the two alcohol groups are oxidized to diketone with moderate yield.
- BBr 3 or HBr/HOAc the protective groups are removed to give clean final products.
- reagents and conditions a) chlorosulfonic acid; b) NHR 1 R 2 , NEt3; c) NHR3R 4 , EDCI, HOBt, NEt 3 ; d) BBr 3 , then MeOH.
- Ar Aryl R 1 ; alkyl
- reagents and conditions a. n-buLi/-78°C/THF then substituted benzenealdehyde; b. H 2 /Pd-C/EtOAc; c. Br 2 /-60 o C/CHCl 3 ; d. n-buLi/- 78°C/THF then CO 2 ; e. SOC1 2 /DMF (cat)/benzene/70°C
- Scheme 5 presents a method to synthesis acyl chlorides with one or more than one carbon linker in 5-position.
- Aromatic bromide can be transformed to aromatic lithium with butyl lithium at low temperature (-78 0 C).
- the lithium reagent is reacted with commercially available substituted benzene aldehyde to obtain compound 2 in high yield. Removal of the hydroxyl group in 2 in a H 2 atmosphere and in presence of a Pd-C catalyst yields 3, which is brominated with Br 2 to afford 4.
- This reaction is regio- selective.
- Using butyl lithium again to exchange bromine in 4 generates another lithium reagent, which is treated with dry ice to afford acids 5.
- Compound 5 is easily transformed to acyl chlorides 6 with SOCl 2 in benzene using DMF as the catalyst.
- reagents and conditions a. n-buLi/-78°C/THF then substituted benzenealdehyde; b. H 2 /Pd-C/EtOAc; c. Br 2 /-6O°C/CHC1 3 ; d. n-buLi/- 78°C/THF then CO 2 ; e. SOC1 2 /DMF (cat)/benzene/70°C
- Scheme 7 discloses a method for the synthesis of acyl chlorides without carbon linker in 5-position.
- Compounds 12 may be afforded in two steps from commercially available compound 9 in high yield. Any compound 10 having a methyl group removed by the bromide to produce compound 11 may be transformed to compound 12 with methylation.
- the Suzuki coupling reaction may be used to generate 13.
- Compounds 13 may be hydrolyzed in a MeOH/KOH system, and then acylated with SOCl 2 to afford acyl chloride in high yield.
- R 1 , R 2 , R 3 , R 4 Aryl, Alkyl,
- A Heterocycle, Aryl, X: heterarom, sulfone, acyl,
- Formula I induce apoptosis and also potentiate the induction of apoptosis in response to apoptosis induction signals. Therefore, it is contemplated that these compounds sensitize cells to inducers of apoptosis, including cells that are resistant to such inducers.
- the anti-apoptotic Bcl-2 family member inhibitors of the present invention can be used to induce apoptosis in any disorder that can be treated, ameliorated, or prevented by the induction of apoptosis.
- the present invention provides compositions and methods for targeting animals characterized as overexpressing an anti-apoptotic Bcl-2 family member protein.
- the cells e.g., cancer cells
- the cells operationally manifest elevated expression levels of anti-apoptotic Bcl-2 family member proteins by virtue of executing the apoptosis program and dying in response to an inhibiting effective amount of a compound of Formula I, said response occurring, at least in part, due to the dependence in such cells on anti-apoptotic Bcl-2 family member protein function for their survival.
- the invention pertains to modulating an apoptosis associated state which is associated with one or more apoptosis modulating agents.
- apoptosis modulating agents include, but are not limited to, Fas/CD95, TRAMP, TNF RI, DRl, DR2, DR3, DR4, DR5, DR6, FADD, RIP, TNF ⁇ , Fas ligand, TRAIL, antibodies to TRAILRl or TRAILR2, Bcl-2, p53, BAX, BAD, Akt, CAD, PB kinase, PPl, and caspase proteins.
- Other agents involved in the initiation, decision and degradation phase of apoptosis are also included.
- apoptosis modulating agents include agents, the activity, presence, or change in concentration of which, can modulate apoptosis in a subject.
- Preferred apoptosis modulating agents are inducers of apoptosis, such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a TNFR-I ligand, or TRAIL.
- compositions and methods of the present invention are used to treat diseased cells, tissues, organs, or pathological conditions and/or disease states in an animal (e.g., a mammalian subject including, but not limited to, humans and veterinary animals).
- an animal e.g., a mammalian subject including, but not limited to, humans and veterinary animals.
- various diseases and pathologies are amenable to treatment or prophylaxis using the present methods and compositions.
- a non-limiting exemplary list of these diseases and conditions includes, but is not limited to, breast cancer, prostate cancer, lymphoma, skin cancer, pancreatic cancer, colon cancer, .
- melanoma malignant melanoma, ovarian cancer, brain cancer, primary brain carcinoma, head-neck cancer, glioma, glioblastoma, liver cancer, bladder cancer, non-small cell lung cancer, head or neck carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, small-cell lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, bladder carcinoma, pancreatic carcinoma, stomach carcinoma, colon carcinoma, prostatic carcinoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, myeloma, multiple myeloma, adrenal carcinoma, renal cell carcinoma, endometrial carcinoma, adrenal cortex carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, choriocarcinoma, mycosis fungoides, malignant hypercalcemia, cervical hyperplasia, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic
- infections suitable for treatment with the compositions and methods of the present invention include, but are not limited to, infections caused by viruses, bacteria, fungi, mycoplasma, prions, and the like.
- Some embodiments of the present invention provide methods for administering an effective amount of a compound of Formula I and at least one additional therapeutic agent (including, but not limited to, chemofherapeutic antineoplastics, apoptosis modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents) and/or therapeutic technique (e.g., surgical intervention, and/or radiotherapies).
- additional therapeutic agent including, but not limited to, chemofherapeutic antineoplastics, apoptosis modulating agents, antimicrobials, antivirals, antifungals, and anti-inflammatory agents
- therapeutic technique e.g., surgical intervention, and/or radiotherapies.
- anticancer agents are contemplated for use in the methods of the present invention. Indeed, the present invention contemplates, but is not limited to, administration of numerous anticancer agents such as: agents that induce apoptosis; polynucleotides (e.g., anti-sense, ribozymes, siRNA); polypeptides (e.g., enzymes and antibodies); biological mimetics (e.g., gossypol or BH3 mimetics); agents that bind (e.g., oligomerize or complex) with a Bcl-2 family protein such as Bax; alkaloids; alkylating agents; antitumor antibiotics; antimetabolites; hormones; platinum compounds; monoclonal or polyclonal antibodies (e.g., antibodies conjugated with anticancer drugs, toxins, defensins), toxins; radionuclides; biological response modifiers (e.g., interferons (e.g., IFN- ⁇ ) and
- anticancer agents comprise agents that induce or stimulate apoptosis.
- Agents that induce apoptosis include, but are not limited to, radiation (e.g., X-rays, gamma rays, UV); tumor necrosis factor (TNF)-related factors (e.g., TNF family receptor proteins, TNF family ligands, TRAIL, antibodies to TRAILRl or TRAILR2); kinase inhibitors (e.g., epidermal growth factor receptor (EGFR) kinase inhibitor, vascular growth factor receptor (VGFR) kinase inhibitor, ' fibroblast growth factor receptor (FGFR) kinase inhibitor, platelet-derived growth factor receptor (PDGFR) kinase inhibitor, and Bcr-Abl kinase inhibitors (such as GLEEVEC)); antisense molecules; antibodies (e.g., HERCEPTIN, RITUXAN, ZEVALIN, and AV
- compositions and methods of the present invention provide a compound of Formula I and at least one anti- hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (e.g., herbs and other plant and/or animal derived compounds).
- at least one anti- hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (e.g., herbs and other plant and/or animal derived compounds).
- Alkylating agents suitable for use in the present compositions and methods include, but are not limited to: 1) nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin); and chlorambucil); 2) ethylenimines and methylmelamines (e.g., hexamethylmelarnine and thiotepa); 3) alkyl sulfonates (e.g., busulfan); 4) nitrosoureas (e.g., carmustine (BCNU); lomustine (CCNU); semustine (methyl-CCNU); and streptozocin (streptozotocin)); and 5) triazenes (e.g, dacarbazine (DTIC; dimethyltriazenoimid-azolecarboxamide).
- nitrogen mustards e.g., mechlorethamine, cyclophosphamide
- antimetabolites suitable for use in the present compositions and methods include, but are not limited to: 1) folic acid analogs (e.g., methotrexate (amethopterin)); 2) pyrimidine analogs (e.g., fluorouracil (5-fiuorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR), and cytarabine (cytosine arabinoside)); and 3) purine analogs (e.g., mercaptopurine (6-niercaptopurine; 6-MP), thioguanine (6-thioguanine; TG), and pentostatin (2 ' -deoxycoformycin)) .
- folic acid analogs e.g., methotrexate (amethopterin)
- pyrimidine analogs e.g., fluorouracil (5-fiuorouracil; 5-FU), floxuridine (fluorode-oxyuridine; FudR
- chemotherapeutic agents suitable for use in the compositions and methods of the present invention include, but are not limited to: 1) vinca alkaloids (e.g., vinblastine (VLB), vincristine); 2) epipodophyllotoxins (e.g., etoposide and teniposide); 3) antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin (daunomycin; rubidomycin), doxorabicin, bleomycin, plicamycin (mithramycin), and mitomycin (mitomycin C)); 4) enzymes (e.g., L-asparaginase); 5) biological response modifiers (e.g., interferon-alfa); 6) platinum coordinating complexes (e.g., cisplatin (cis-DDP) and carboplatin); 7) anthracenediones (e.g., mitoxantrone
- vinca alkaloids e
- any oncolytic agent that is routinely used in a cancer therapy context finds use in the compositions and methods of the present invention.
- the U.S. Food and Drug Administration maintains a formulary of oncolytic agents approved for use in the United States. International counterpart agencies to the U.S.F.D.A. maintain similar formularies.
- Table 1 provides a list of exemplary antineoplastic agents approved for use in the U.S. Those skilled in the art will appreciate that the "product labels" required on all U.S. approved chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the exemplary agents.
- Preferred conventional anticancer agents for use in administration with the present compounds include, but are not limited to, adriamycin, 5- fluorouracil, etoposide, camptothecin, actinomycin D, mitomycin C, cisplatin, docetaxel, gemcitabine, carboplatin, oxaliplatin, bortezomib, gefitinib, and bevacizumab. These agents can be prepared and used singularly, in combined therapeutic compositions, in kits, or in combination with immunotherapeutic agents, and the like.
- the present invention provides methods for administering a compound of Formula I with radiation therapy.
- the invention is not limited by the types, amounts, or delivery and administration systems used to deliver the therapeutic dose of radiation to an animal.
- the animal may receive photon radiotherapy, particle beam radiation therapy, other types of radiotherapies, and combinations thereof.
- the radiation is delivered to the animal using a linear accelerator.
- the radiation is delivered using a gamma knife. 2005/029634
- the source of radiation can be external or internal to the animal.
- External radiation therapy is most common and involves directing a beam of high-energy radiation to a tumor site through the skin using, for instance, a linear accelerator. While the beam of radiation is localized to the tumor site, it is nearly impossible to avoid exposure of normal, healthy tissue. However, external radiation is usually well tolerated by patients.
- Internal radiation therapy involves implanting a radiation-emitting source, such as beads, wires, pellets, capsules, particles, and the like, inside the body at or near the tumor site including the use of delivery systems that specifically target cancer cells (e.g., using particles attached to cancer cell binding ligands). Such implants can be removed following treatment, or left in the body inactive.
- Types of internal radiation therapy include, but are not limited to, brachytherapy, interstitial irradiation, intracavity irradiation, radioimmunotherapy, and the like.
- the animal may optionally receive radiosensitizers (e.g., metronidazole, misonidazole, intra-arterial Budr, intravenous iododeoxyuridine (IudR), nitroimidazole, 5-substituted-4-nitroimidazoles, 2H- isoindolediones, [[(2-bromoethyl)-amino]methyl]-nitro-lH-imidazole-l- ethanol, nitroaniline derivatives, DNA-aff ⁇ nic hypoxia selective cytotoxins, halogenated DNA ligand, 1,2,4 benzotriazine oxides, 2-nitroimidazole derivatives, fluorine-containing nitroazole derivatives, benzamide, nicotinamide, acridine-intercalator, 5-thiotretrazole derivative, 3-nitro-l,2,4- triazole, 4,5-dinitroimidazole derivative, hydroxylated texaph
- any type of radiation can be administered to a patient, so long as the dose of radiation is tolerated by the patient without unacceptable negative side-effects.
- Suitable types of radiotherapy include, for example, ionizing (electromagnetic) radiotherapy (e.g., X-rays or gamma rays) or particle beam radiation therapy (e.g., high linear energy radiation).
- Ionizing radiation is defined as radiation comprising particles or photons that have sufficient energy to produce ionization, i.e., gain or loss of electrons (as described in, for example, U.S. 5,770,581 incorporated herein by reference in its entirety).
- the effects of radiation can be at least partially controlled by the clinician.
- the dose of radiation is preferably fractionated for maximal target cell exposure and reduced toxicity.
- the total dose of radiation administered to an animal preferably is about .01 Gray (Gy) to about 100 Gy. More preferably, about 10 Gy to about 65 Gy (e.g., about 15 Gy, 20 Gy, 25 Gy, 30 Gy, 35 Gy, 40 Gy, 45 Gy, 50 Gy, 55 Gy, or 60 Gy) are administered over the course of treatment. While in some embodiments a complete dose of radiation can be administered over the course of one day, the total dose is ideally fractionated and administered over several days. Desirably, radiotherapy is administered over the course of at least about 3 days, e.g., at least 5, 7, 10, 14, 17, 21, 25, 28, 32, 35, 38, 42, 46, 52, or 56 days (about 1-8 weeks).
- a daily dose of radiation will comprise approximately 1-5 Gy (e.g., about 1 Gy, 1.5 Gy, 1.8 Gy, 2 Gy, 2.5 Gy, 2.8 Gy, 3 Gy, 3.2 Gy, 3.5 Gy, 3.8 Gy, 4 Gy, 4.2 Gy, or 4.5 Gy), preferably 1-2 Gy (e.g., 1.5-2 Gy).
- the daily dose of radiation should be sufficient to induce destruction of the targeted cells.
- radiation preferably is not administered every day, thereby allowing the animal to rest and the effects of the therapy to be realized.
- radiation desirably is administered on 5 consecutive days, and not administered on 2 days, for each week of treatment, thereby allowing 2 days of rest per week.
- radiation can be administered 1 day/week, 2 days/week, 3 days/week, 4 days/week, 5 days/week, 6 days/week, or all 7 days/week, depending on the animal's responsiveness and any potential side effects.
- Radiation therapy can be initiated at any time in the therapeutic period.
- radiation is initiated in week 1 or week 2, and is administered for the remaining duration of the therapeutic period.
- radiation is administered in weeks 1-6 or in weeks 2-6 of a therapeutic period comprising 6 weeks for treating, for instance, a solid tumor.
- radiation is administered in weeks 1-5 or weeks 2-5 of a therapeutic period comprising 5 weeks.
- Antimicrobial therapeutic agents may also be used as therapeutic agents in the present invention. Any agent that can kill, inhibit, or otherwise attenuate the function of microbial organisms may be used, as well as any agent contemplated to have such activities.
- Antimicrobial agents include, but are not limited to, natural and synthetic antibiotics, antibodies, inhibitory proteins (e.g., defensins), antisense nucleic acids, membrane disruptive agents and the like, used alone or in combination. Indeed, any type of antibiotic may be used including, but not limited to, antibacterial agents, antiviral agents, antifungal agents, and the like.
- Formula I and one or more therapeutic agents or anticancer agents are administered to an animal under one or more of the following conditions: at different periodicities, at different durations, at different concentrations, by different administration routes, etc.
- the compound is administered prior to the therapeutic or anticancer agent, e.g., 0.5, 1, 2 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, 1, 2, 3, or 4 weeks prior to the administration of the therapeutic or anticancer agent.
- the compound is administered after the therapeutic or anticancer agent, e.g., 0.5, 1, 2 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, 1, 2, 3, or 4 weeks after the administration of the anticancer agent.
- the compound and the therapeutic or anticancer agent are administered concurrently but on different schedules, e.g., the compound is administered daily while the therapeutic or anticancer agent is administered once a week, once every two weeks, once every three weeks, or once every four weeks. In other embodiments, the compound is administered once a week while the therapeutic or anticancer agent is administered daily, once a week, once every two weeks, once every three weeks, or once every four weeks.
- compositions within the scope of this invention include all compositions wherein the compounds of the present invention are contained in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
- the compounds may be administered to mammals, e.g. humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for disorders responsive to induction of apoptosis.
- about 0.01 to about 10 mg/kg is orally administered to treat, ameliorate, or prevent such disorders.
- the dose is generally about one-half of the oral dose.
- a suitable intramuscular dose would be about 0.0025 to about 25 mg/kg, and most preferably, from about 0.01 to about 5 mg/kg.
- the unit oral dose may comprise from about 0.01 to about 1000 mg, preferably about 0.1 to about 100 mg of the compound.
- the unit dose may be administered one or more times daily as one or more tablets or capsules each containing from about 0.1 to about 10, conveniently about 0.25 to 50 mg of the compound or its solvates.
- the compound may be present at a concentration of about 0.01 to 100 mg per gram of carrier. In a preferred embodiment, the compound is present at a concentration of about 0.07-1.0 mg/ml, more preferably, about 0.1-0.5 mg/ml, most preferably, about 0.4 mg/ml.
- the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
- the preparations particularly those preparations which can be administered orally or topically and which can be used for the preferred type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, shampoos and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by injection, topically or orally, contain from about 0.01 to 99 percent, preferably from about 0.25 to 75 percent of active compound(s), together with the excipient.
- compositions of the invention may be administered to any animal which may experience the beneficial effects of the compounds of the invention.
- animals are mammals, e.g., humans, although the invention is not intended to be so limited.
- Other animals include veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like).
- the compounds and pharmaceutical compositions thereof may be administered by any means that achieve their intended purpose.
- administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, intranasal or topical routes.
- administration may be by the oral route.
- the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- compositions of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes.
- pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
- fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose,
- disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, cross- linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate.
- Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
- Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices.
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
- suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylrnethyl-cellulose phthalate, are used.
- Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
- Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
- the push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
- stabilizers may be added.
- Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base.
- Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
- gelatin rectal capsules which consist of a combination of the active compounds with a base.
- Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
- Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form, for example, water- soluble salts and alkaline solutions.
- suspensions of the active compounds as appropriate oily injection suspensions may be administered.
- Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides or polyethylene glycol-400.
- Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
- the suspension may also contain stabilizers.
- the topical compositions of this invention are formulated preferably as oils, creams, lotions, ointments and the like by choice of appropriate carriers.
- Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C 12 ).
- the preferred carriers are those in which the active ingredient is soluble.
- Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired.
- transdermal penetration enhancers can be employed in these topical formulations. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762.
- Creams are preferably formulated from a mixture of mineral oil, self- emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil such as almond oil, is admixed.
- a typical example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
- Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool.
- a vegetable oil such as almond oil
- a typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.
- Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.
- TW-58 N-[3-Methyl-4-(2-tert-butyl-benzenesulfonyl)-phenyl]-2,3,4- trihydroxy-5-(2-isopropyl-benzyl)-benzamide
- TW-80 N-[2-Methyl-5-(4-chloro-phenylsulfamoyl)-phenyl]-2,3 ,4- trihydroxy-5-(2-isopropyl-ben2yl)-benzamide
- TW-202 4-Chloro-3-[4-(3,4-dihydro-lH-isoquinoline-2-sulfonyl)- benzoylamino]-5-(methyl-phenetliyl-sulfamoyl)-benzoic acid
- TW-204 4-Chloro-3-(4-methoxy-benzoylamino)-5-(methyl-phenethyl- sulfamoyl)-benzoic acid
- TM-1241 2- ⁇ 2,3,4-Trihydroxy-5-[methyl-(4- ⁇ henyl-butyl)-sulfamoyl]- benzoyl ⁇ -l,2 3 3,4-tetrahydro-isoquinoline-7-sulfonic acid methyl-phenethyl- amide
- TM-1260 6-[Methyl-(2,3,4-trihydroxy-5-isopropyl-benzenesulfonyl)-amino]- naphthalene-2-carboxylic acid isobutyl-amide
- a 21 -residue Bid BH3 peptide (QEDIIRNIARHLAQ VGDSMDR)
- assay buffer 100 mM potassium phosphate, pH 7.5; 100 ⁇ g/ml bovine gamma globulin; 0.02% sodium azide, purchased from Invitrogen Corporation, Life Technologies
- the bound peptide control containing Bcl-2 and Flu-Bid-21 peptide (equivalent to 0% inhibition), and free peptide control containing only free Flu-Bid-21 (equivalent to 100% inhibition), are included on each assay plate.
- the polarization values in milipolarization units (mP) are measured at excitation wavelength at 485 ntn and an emission wavelength at 530 run, after 4 hours incubation when the binding reached equilibrium, using the Ultra plate reader (Tecan U.S. Inc., Research Triangle Park, NC).
- ICso the inhibitor concentration at which 50% of bound peptide is displaced, is determined from the plot using nonlinear least-squares analysis and curve fitting using GraphPad Prism ® software.
- the unlabeled Bid peptide is used as the positive control.
- the Kj values were calculated using our developed equation for FP assay (Nikolovska-Coleska et at, Anal. Biochem., 2004, in press).
- the program for calculating a K; value is available free of charge via the Internet at http://swl6.im.med.umich.edu/software/calc_ki/.
- Bcl-xL recombinant His-tagged protein without the C-terminus hydrophobic tail and the Bak-16mer BH3 peptide labeled with 6-carboxyfluorescein succinimidyl ester (FAM) were used.
- the competitive binding assay was performed in the same way as for Bcl-2 protein using a preincubated complex with 60 nM Bcl-xL and 5 nM Flu-Bak peptide in assay buffer containing 50 mM Tris-Bis, pH 7.4; 0.01% bovine gamma globulin.
- Example 1 The compounds described in Example 1 were tested for their binding affinity to Bcl-2 using the fluorescence polarization assay.
- the following compounds had 1.0 ⁇ M or lower IC50 values for Bcl-2: TM-1216, 197, 1213, 1203, 1207, 1208, 1209, 1210, 1211, 1205, 1206, 190, 192, 121, and 122, and TW-37, 38, 45, 46, 47, 60, 61, 159, 164, 165, 166, 169, and 172.
- the following compounds had higher than 1.0 ⁇ M IC 5 0 values for Bcl-2: TM-174, 175, 176, 178, 1214, 1215, 194, 195, 196, 198, 193, 1212, 199, 1200, 1202, 1217, 1201, 105, 106, 107, 108, 129, and 142 and TW-I, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 24, 25, 27, 28, 21, 16, 17, 20, 22, 23, 34, 35, 39, 41, 42, 55, 52, 53, 56, 160, 161, 162, 163, 167, 170, 173, and 174.
- the following compounds had 1.0 ⁇ M or lower IC 50 values for Bcl-xL: TM-171.
- the following compounds had higher than 1.0 ⁇ M IC50 values for Bcl-xL: TM- 174, 175, 176, 178, 1214, 1215, 194, 1216, 195, 198, 193, 190, 192, 1201, 105, 106, 107, 129, 142, 159, 1210, 199, 1200, 1202, 1217, 1205, 1206, 162, 163, 133, 165, 167, 168, 169, 183, 180, 196, 197, 1213, 1203, 108, 121, 122, 140, 141, 157, 1207, 1208, 1209, 1211, 1212, and 179.
- HSQC Heteronuclear Single Quantum Coherence Spectroscopy
- TW-37 was administered to five different cancer cell lines. LnCap, PC-3, and DU145c prostate cancer cell lines and 2LMP and MCF-IOA breast cancer cell line were each seeded in 96- well plates with increasing concentrations of TW-37. The cells were then incubated at 37 0 C with 5% CO 2 for 5 days, followed by detection of cell viability with MTT. Untreated cells were used as 100% growth. TW-37 inhibited the cell growth of each of the cell lines, with an IC 50 in the range of about 1-5 ⁇ M ( Figure 2). These data indicate that TW-37 is capable of inhibiting cell growth in human cancer cells.
- PC-3 cells were grown as above and increasing concentrations of compounds were added. Cell viability was then assayed using WST ( Figure 3). The results show that all of the tested compounds had the ability to inhibit the growth of prostate cancer cells, with most compounds having an IC5 0 in the range of about 0.5-10 ⁇ M.
- Compounds of the present invention were also tested for their effect on cell growth of MDA-MB-231 (2LMP) cells. Cells were grown as above and increasing concentrations of compounds were added. Cell viability was then assayed using WST. The results show that all of the tested compounds had the ability to inhibit the growth of prostate cancer cells, with most compounds having an IC50 in the range of about 0.1-20 ⁇ M.
- Those compounds within this range are: TM-103, 104, 105, 106, 107, 108, 109, HO 5 111, 121, 122, 125, 126, 127, 128, 129, 130, 132, 133,134, 135, 136, 137, 140, 141, 142, 144, 145, 146, 147, 148, 149, 150, 152, 153, 154, 155, 156, 165, 166, 167, 168, 169, 170, and 171.
- Those compounds above 20 ⁇ M are: TM- 124 and 143.
- TW-37 Activates Caspase-3 in Prostate Cancer PC-3 Cells
- PC-3 cells and PrEC human normal prostate epithelial cells
- PrEC human normal prostate epithelial cells
- CaspGlow Red Active Capsase-3 Staining Kit Bio Vision, Inc.
- rhodaniine-DEVD-FMK SEQ ID NO:1 binds covalently to active caspase-3 in apoptotic cells.
- the specific caspase-3 inhibitor Z-DEVD-FMK (1 ⁇ g/ml) was added in parallel tubes to inhibit caspase-3 activation.
- the cells were analyzed by flow cytometry in the red channel and the results are shown as percent of cells having active caspase-3 (Figure 5).
- the results show that treatment of PC-3 cells with TW-37 results in the activation of caspase-3 within the cells, with 5 ⁇ M TW-37 resulting in about 60% of the cells having activated caspase-3 ( Figure 5).
- Addition of the caspase inhibitor Z-DEVD- FMK blocked the activation of caspase-3.
- TW-37 had no effect on normal prostate epithelial cells.
- TW-37 Enhances Cisplatin-Induced Apoptosis in Breast Cancer MDA-
- CDDP is a DNA damaging agent and can effectively induce apoptosis in MDA-231 breasted cancer cells and is also a clinically used chemotherapeutic drug for cancer.
- MDA-231 cells were treated with CDDP and TW-37 alone or in combination for 42 hours and cell survival was analyzed. Exposure to CDDP resulted in decreased cell survival with an IC 50 of around 0.75 ⁇ M ( Figure 6). The addition of 0.2 ⁇ M or 0.3 ⁇ M TW-37 enhanced the CDDP induced cell death, with 0.3 ⁇ M TW-37 lowering the IC 50 of CDDP by about half ( Figure 6). The results show that TW-37 is effective to potentiate the activity of CDDP in inducing cell death in MDA-231 cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05806407A EP1778206A4 (en) | 2004-08-20 | 2005-08-22 | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
CA002577752A CA2577752A1 (en) | 2004-08-20 | 2005-08-22 | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
BRPI0514504-0A BRPI0514504A (en) | 2004-08-20 | 2005-08-22 | small inhibitory molecules of the anti-apoptotic bcl-2 family members and their uses |
JP2007528060A JP2008511548A (en) | 2004-08-20 | 2005-08-22 | Small molecule inhibitors of anti-apoptotic BCL-2 family members and methods of use thereof |
AU2005277223A AU2005277223C1 (en) | 2004-08-20 | 2005-08-22 | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
MX2007002104A MX2007002104A (en) | 2004-08-20 | 2005-08-22 | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof. |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60341104P | 2004-08-20 | 2004-08-20 | |
US60/603,411 | 2004-08-20 | ||
US11/209,998 US8557812B2 (en) | 2004-08-20 | 2005-08-22 | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006023778A2 true WO2006023778A2 (en) | 2006-03-02 |
WO2006023778A3 WO2006023778A3 (en) | 2006-06-15 |
Family
ID=36181553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/029634 WO2006023778A2 (en) | 2004-08-20 | 2005-08-22 | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US8557812B2 (en) |
JP (1) | JP2008511548A (en) |
KR (1) | KR20070046180A (en) |
AU (1) | AU2005277223C1 (en) |
BR (1) | BRPI0514504A (en) |
CA (1) | CA2577752A1 (en) |
WO (1) | WO2006023778A2 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009051244A1 (en) | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US7700625B2 (en) | 2005-04-13 | 2010-04-20 | Astex Therapeutics Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2013096049A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096059A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096060A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP2829539A1 (en) * | 2013-07-23 | 2015-01-28 | Les Laboratoires Servier | New pyrrole derivatives, method of preparing same and pharmaceutical compositions containing them |
WO2015011396A1 (en) * | 2013-07-23 | 2015-01-29 | Les Laboratoires Servier | Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same |
WO2015011397A1 (en) * | 2013-07-23 | 2015-01-29 | Les Laboratoires Servier | Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same |
WO2015011164A1 (en) * | 2013-07-23 | 2015-01-29 | Les Laboratoires Servier | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
US20150051177A1 (en) * | 2009-03-02 | 2015-02-19 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell |
WO2015115805A1 (en) * | 2014-01-28 | 2015-08-06 | 한국생명공학연구원 | Novel 2-phenylbenzofuran derivative or pharmaceutically acceptable salt thereof, production method for same and pharmaceutical composition for preventing or treating inflammatory disease comprising same as active ingredient |
US9428439B2 (en) | 2006-10-12 | 2016-08-30 | Astex Therapeutics Ltd. | Hydrobenzamide derivatives as inhibitors of Hsp90 |
US9730912B2 (en) | 2006-10-12 | 2017-08-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
CN108017585A (en) * | 2017-12-15 | 2018-05-11 | 广西壮族自治区中医药研究院 | A kind of gallic acid sulphone amide derivative and its application in anti-liver cancer and anti- |
US10053443B2 (en) | 2014-01-28 | 2018-08-21 | Korea Research Institute Of Bioscience And Biotechnology | 2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease |
US10258626B2 (en) | 2012-01-24 | 2019-04-16 | Les Laboratories Servier | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them |
WO2019144117A1 (en) | 2018-01-22 | 2019-07-25 | Bioventures, Llc | Bcl-2 proteins degraders for cancer treatment |
WO2019210828A1 (en) | 2018-04-29 | 2019-11-07 | Beigene, Ltd. | Bcl-2 INHIBITORS |
EP3468546A4 (en) * | 2016-06-09 | 2020-04-01 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
US10758524B2 (en) | 2014-07-22 | 2020-09-01 | Bioventures, Llc | Compositions and methods for selectively depleting senescent cells |
US10786519B2 (en) | 2015-02-23 | 2020-09-29 | Mayo Foundation For Medical Education And Research | Methods and materials for treating human immunodeficiency virus infections |
US10807977B2 (en) | 2016-04-21 | 2020-10-20 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
EP3669869A4 (en) * | 2017-04-10 | 2020-10-28 | Shi, Jianyou | Drug for treating tumor diseases, and having antibacterial, antivirus and anti-inflammatory effects |
WO2021105720A3 (en) * | 2019-11-29 | 2021-07-22 | Oxular Limited | Pharmaceutical compositions and formulations for the treatment of retinoblastoma |
WO2021162668A1 (en) * | 2020-02-11 | 2021-08-19 | Bahcesehir Universitesi | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor |
WO2021162664A1 (en) * | 2020-02-11 | 2021-08-19 | Bahcesehir Universitesi | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor |
US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
WO2023107606A1 (en) | 2021-12-09 | 2023-06-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
US11938098B2 (en) | 2015-04-20 | 2024-03-26 | Mayo Foundation For Medical Education And Research | Method for killing HIV-infected cells using Bcl-2 inhibitors |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
WO2008044045A1 (en) * | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044041A1 (en) * | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044027A2 (en) * | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical compounds having hsp90 inhibitory or modulating activity |
US8168645B2 (en) | 2006-11-15 | 2012-05-01 | Genentech, Inc. | Arylsulfonamide compounds |
GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
JP5322527B2 (en) * | 2008-07-17 | 2013-10-23 | 浜松ホトニクス株式会社 | Compounds suitable for detecting apoptosis |
CN102099339A (en) * | 2008-07-18 | 2011-06-15 | 武田药品工业株式会社 | Benzazepine derivatives and their use as hstamine h3 antagonists |
US8865901B2 (en) | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
WO2011041731A2 (en) * | 2009-10-02 | 2011-04-07 | Fred Hutchinson Cancer Research Center | Method of inhibiting bcl-2-related survival proteins |
US20110172204A1 (en) * | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Compounds and their use |
AU2012209295B2 (en) | 2011-01-25 | 2016-06-30 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
US20150218103A1 (en) | 2012-08-25 | 2015-08-06 | The Johns Hopkins University | Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness |
US9096625B2 (en) | 2013-01-16 | 2015-08-04 | The Regents Of The University Of Michigan | BCL-2/BCL-XL inhibitors and therapeutic methods using the same |
US9783519B2 (en) * | 2015-06-18 | 2017-10-10 | Hong Kong Baptist University | Palladium/silver co-catalyzed tandem reactions synthesis of phenylacetophenone derivatives by oxabenzonorbornadienes with terminal alkynes and their anti-tumor or anti-cancer activities |
BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana Farber Cancer Inst Inc | inhibitor resistance mechanism |
CN116675677B (en) * | 2023-08-02 | 2023-09-26 | 中国林业科学研究院林产化学工业研究所 | C8 urushiol derivative and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2686123A (en) * | 1951-07-19 | 1954-08-10 | Us Agriculture | Stabilization of dehydrated vegetable material |
US4394389A (en) | 1979-03-01 | 1983-07-19 | Riet Bartholomeus Van T | Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors |
JPS60163812A (en) | 1984-02-03 | 1985-08-26 | Zenyaku Kogyo Kk | Antiallergic agent |
US5385936A (en) * | 1990-07-12 | 1995-01-31 | The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services | Gossypol acetic acid for the treatment of cancer |
EP0614354B1 (en) | 1991-11-25 | 2001-01-17 | Richardson-Vicks, Inc. | Use of salicylic acid for regulating skin atrophy |
DE19726871C1 (en) | 1997-06-24 | 1999-03-04 | Werner Kreutz | Synergistic compositions for the selective control of tumor tissue |
US6201028B1 (en) | 1998-12-08 | 2001-03-13 | The Rockefeller University | Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs |
HUP0302479A2 (en) | 2001-03-27 | 2003-11-28 | Daiichi Suntory Biomedical Research Limited | Nf-kappa b inhibitor pharmaceutical composition containing substituted benzoic acid derivative as active ingredient |
-
2005
- 2005-08-22 WO PCT/US2005/029634 patent/WO2006023778A2/en active Application Filing
- 2005-08-22 CA CA002577752A patent/CA2577752A1/en not_active Abandoned
- 2005-08-22 US US11/209,998 patent/US8557812B2/en active Active
- 2005-08-22 AU AU2005277223A patent/AU2005277223C1/en not_active Ceased
- 2005-08-22 BR BRPI0514504-0A patent/BRPI0514504A/en not_active IP Right Cessation
- 2005-08-22 KR KR1020077006335A patent/KR20070046180A/en not_active Application Discontinuation
- 2005-08-22 JP JP2007528060A patent/JP2008511548A/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of EP1778206A4 * |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9914719B2 (en) | 2005-04-13 | 2018-03-13 | Astex Therapeutics Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 |
US7700625B2 (en) | 2005-04-13 | 2010-04-20 | Astex Therapeutics Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 |
US8101648B2 (en) | 2005-04-13 | 2012-01-24 | Astex Therapeutics, Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
US8106057B2 (en) | 2006-03-01 | 2012-01-31 | Astex Therapeutics, Ltd. | Dihydroxyphenyl isoindolylmethanones |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
US9428439B2 (en) | 2006-10-12 | 2016-08-30 | Astex Therapeutics Ltd. | Hydrobenzamide derivatives as inhibitors of Hsp90 |
US9730912B2 (en) | 2006-10-12 | 2017-08-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
US9487509B2 (en) | 2007-10-18 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US8586571B2 (en) | 2007-10-18 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2009051244A1 (en) | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US11834446B2 (en) | 2009-03-02 | 2023-12-05 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell |
US9862714B2 (en) | 2009-03-02 | 2018-01-09 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell |
US11512081B2 (en) | 2009-03-02 | 2022-11-29 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell |
US10975067B2 (en) | 2009-03-02 | 2021-04-13 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell |
US9416101B2 (en) | 2009-03-02 | 2016-08-16 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell |
US20150051177A1 (en) * | 2009-03-02 | 2015-02-19 | Stemsynergy Therapeutics, Inc. | Methods and compositions useful in treating cancer and reducing wnt mediated effects in a cell |
WO2013096049A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CN104125955A (en) * | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | Compounds for inhibiting interaction of bcl2 with binding partners |
WO2013096060A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096059A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CN104125953A (en) * | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | Compounds for inhibiting interaction of bcl2 with binding partners |
US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
US9126979B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
US10258626B2 (en) | 2012-01-24 | 2019-04-16 | Les Laboratories Servier | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them |
US9809574B2 (en) | 2013-07-23 | 2017-11-07 | Les Laboratoires Servier | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
RU2689305C2 (en) * | 2013-07-23 | 2019-05-27 | Ле Лаборатуар Сервье | Novel isoindoline or isoquinoline compounds, method for production thereof and pharmaceutical compositions containing thereof |
US9108983B2 (en) | 2013-07-23 | 2015-08-18 | Les Laboratoires Servier | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
JP2015028018A (en) * | 2013-07-23 | 2015-02-12 | レ ラボラトワール セルヴィエ | Novel pyrrole compounds, process for their preparation and pharmaceutical compositions containing them |
CN104341395A (en) * | 2013-07-23 | 2015-02-11 | 瑟维尔实验室 | Novel pyrrole derivatives, method for the production thereof and pharmaceutical compositions containing same |
CN105431422A (en) * | 2013-07-23 | 2016-03-23 | 法国施维雅药厂 | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
KR20160033224A (en) * | 2013-07-23 | 2016-03-25 | 르 라보레또레 쎄르비에르 | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
KR20160034387A (en) * | 2013-07-23 | 2016-03-29 | 르 라보레또레 쎄르비에르 | Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same |
KR20160034384A (en) * | 2013-07-23 | 2016-03-29 | 르 라보레또레 쎄르비에르 | Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same |
KR20150011786A (en) * | 2013-07-23 | 2015-02-02 | 르 라보레또레 쎄르비에르 | New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
MD20140072A2 (en) * | 2013-07-23 | 2015-01-31 | Les Laboratoires Servier | New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them |
FR3008976A1 (en) * | 2013-07-23 | 2015-01-30 | Servier Lab | "NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM" |
KR101712111B1 (en) | 2013-07-23 | 2017-03-03 | 르 라보레또레 쎄르비에르 | New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
US9598427B2 (en) | 2013-07-23 | 2017-03-21 | Les Laboratoires Servier | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
EP3168217A1 (en) * | 2013-07-23 | 2017-05-17 | Les Laboratoires Servier | Novel indole and pyrrole derivatives, method for preparing same and pharmaceutical compositions containing same |
FR3008975A1 (en) * | 2013-07-23 | 2015-01-30 | Servier Lab | NOVEL PYRROLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US9765056B2 (en) | 2013-07-23 | 2017-09-19 | Les Laboratoires Servier | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
EP2829539A1 (en) * | 2013-07-23 | 2015-01-28 | Les Laboratoires Servier | New pyrrole derivatives, method of preparing same and pharmaceutical compositions containing them |
FR3008978A1 (en) * | 2013-07-23 | 2015-01-30 | Servier Lab | "NOVEL INDOLE AND PYRROLE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM" |
EA028609B1 (en) * | 2013-07-23 | 2017-12-29 | Ле Лаборатуар Сервье | Novel indole and pyrrole compounds, process for preparation thereof and pharmaceutical compositions containing same |
FR3008977A1 (en) * | 2013-07-23 | 2015-01-30 | Servier Lab | NOVEL ISOINDOLINE OR ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
WO2015011400A1 (en) * | 2013-07-23 | 2015-01-29 | Les Laboratoires Servier | Novel pyrrole derivatives, method for the production thereof and pharmaceutical compositions containing same |
US9944620B2 (en) | 2013-07-23 | 2018-04-17 | Les Laboratoires Servier | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them |
WO2015011396A1 (en) * | 2013-07-23 | 2015-01-29 | Les Laboratoires Servier | Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same |
AU2014295101B2 (en) * | 2013-07-23 | 2018-05-31 | Les Laboratoires Servier | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
EA030323B1 (en) * | 2013-07-23 | 2018-07-31 | Ле Лаборатуар Сервье | Indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same |
KR102337149B1 (en) | 2013-07-23 | 2021-12-07 | 르 라보레또레 쎄르비에르 | Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same |
AU2014294867B2 (en) * | 2013-07-23 | 2018-10-04 | Les Laboratoires Servier | Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same |
WO2015011164A1 (en) * | 2013-07-23 | 2015-01-29 | Les Laboratoires Servier | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
US11058689B2 (en) | 2013-07-23 | 2021-07-13 | Les Laboratoires Servier | Pyrrole compounds, a process for their preparation and pharmaceutical |
US10265323B2 (en) | 2013-07-23 | 2019-04-23 | Les Laboratoires Servier | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
US11028070B2 (en) | 2013-07-23 | 2021-06-08 | Les Laboratoires Servier | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
EA032301B1 (en) * | 2013-07-23 | 2019-05-31 | Ле Лаборатуар Сервье | Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them |
WO2015011397A1 (en) * | 2013-07-23 | 2015-01-29 | Les Laboratoires Servier | Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same |
KR102007516B1 (en) | 2013-07-23 | 2019-08-05 | 르 라보레또레 쎄르비에르 | Novel indolizine derivatives, method for the production thereof and pharmaceutical compositions containing same |
KR102008431B1 (en) | 2013-07-23 | 2019-08-07 | 르 라보레또레 쎄르비에르 | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
CN105431422B (en) * | 2013-07-23 | 2019-08-30 | 法国施维雅药厂 | New isoindoline or isoquinoline compound, preparation method and the Pharmaceutical composition containing them |
US10414754B2 (en) | 2013-07-23 | 2019-09-17 | Les Laboratoires Servier | Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them |
US10688101B2 (en) | 2013-07-23 | 2020-06-23 | Les Laboratories Servier | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
US10689364B2 (en) | 2013-07-23 | 2020-06-23 | Les Laboratoires Servier | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
US10662173B2 (en) | 2013-07-23 | 2020-05-26 | Les Laboratoires Servier | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them |
WO2015115805A1 (en) * | 2014-01-28 | 2015-08-06 | 한국생명공학연구원 | Novel 2-phenylbenzofuran derivative or pharmaceutically acceptable salt thereof, production method for same and pharmaceutical composition for preventing or treating inflammatory disease comprising same as active ingredient |
US10053443B2 (en) | 2014-01-28 | 2018-08-21 | Korea Research Institute Of Bioscience And Biotechnology | 2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease |
US11331328B2 (en) | 2014-05-05 | 2022-05-17 | Bioventures, Llc | Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents |
US10758524B2 (en) | 2014-07-22 | 2020-09-01 | Bioventures, Llc | Compositions and methods for selectively depleting senescent cells |
US10786519B2 (en) | 2015-02-23 | 2020-09-29 | Mayo Foundation For Medical Education And Research | Methods and materials for treating human immunodeficiency virus infections |
US11376268B2 (en) | 2015-02-23 | 2022-07-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating human immunodeficiency virus infections |
US11938098B2 (en) | 2015-04-20 | 2024-03-26 | Mayo Foundation For Medical Education And Research | Method for killing HIV-infected cells using Bcl-2 inhibitors |
US10265279B2 (en) | 2016-03-15 | 2019-04-23 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
US10807977B2 (en) | 2016-04-21 | 2020-10-20 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
US11319316B2 (en) | 2016-04-21 | 2022-05-03 | Bioventures, Llc | Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof |
US10927070B2 (en) | 2016-06-09 | 2021-02-23 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
EP3468546A4 (en) * | 2016-06-09 | 2020-04-01 | Cedars-Sinai Medical Center | Compositions and methods for treating cancer |
EP3669869A4 (en) * | 2017-04-10 | 2020-10-28 | Shi, Jianyou | Drug for treating tumor diseases, and having antibacterial, antivirus and anti-inflammatory effects |
CN108017585A (en) * | 2017-12-15 | 2018-05-11 | 广西壮族自治区中医药研究院 | A kind of gallic acid sulphone amide derivative and its application in anti-liver cancer and anti- |
WO2019144117A1 (en) | 2018-01-22 | 2019-07-25 | Bioventures, Llc | Bcl-2 proteins degraders for cancer treatment |
WO2019210828A1 (en) | 2018-04-29 | 2019-11-07 | Beigene, Ltd. | Bcl-2 INHIBITORS |
WO2021105720A3 (en) * | 2019-11-29 | 2021-07-22 | Oxular Limited | Pharmaceutical compositions and formulations for the treatment of retinoblastoma |
GB2606887A (en) * | 2019-11-29 | 2022-11-23 | Oxular Ltd | Pharmaceutical compositions and formulations for the treatment of retinoblastoma |
WO2021162664A1 (en) * | 2020-02-11 | 2021-08-19 | Bahcesehir Universitesi | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor |
WO2021162668A1 (en) * | 2020-02-11 | 2021-08-19 | Bahcesehir Universitesi | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor |
WO2023107606A1 (en) | 2021-12-09 | 2023-06-15 | University Of Florida Research Foundation, Incorporated | Bcl-xl/bcl-2 dual degraders for treatment of cancers |
Also Published As
Publication number | Publication date |
---|---|
US20060084647A1 (en) | 2006-04-20 |
AU2005277223B2 (en) | 2008-10-09 |
AU2005277223A1 (en) | 2006-03-02 |
AU2005277223C1 (en) | 2009-05-21 |
WO2006023778A3 (en) | 2006-06-15 |
JP2008511548A (en) | 2008-04-17 |
CA2577752A1 (en) | 2006-03-02 |
US8557812B2 (en) | 2013-10-15 |
BRPI0514504A (en) | 2008-06-10 |
KR20070046180A (en) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006023778A2 (en) | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof | |
EP1778206A2 (en) | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof | |
EP3125884B1 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
WO2006099193A2 (en) | Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof | |
US9486422B2 (en) | Small molecule inhibitors of Mcl-1 and the uses of thereof | |
DK2019671T3 (en) | Intermediates for the preparation of bivalent SMAC mimetics | |
AU2005228998B2 (en) | Gossypol co-crystals and the use thereof | |
WO2006050447A2 (en) | Apogossypolone and the uses thereof | |
EP1715882A2 (en) | Smac peptidomimetics and the uses thereof | |
WO2006091837A2 (en) | Small molecule inhibitors of stat3 and the uses thereof | |
WO2013149124A1 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
US20190308942A1 (en) | Small molecule inducers of reactive oxygen species and inhibitors of mitochondrial activity | |
EP3285583B1 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
KR100887045B1 (en) | Conformationally constrained smac mimetics and the uses thereof | |
NZ617580B2 (en) | Spiro-oxindole mdm2 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2577752 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/002104 Country of ref document: MX Ref document number: 2007528060 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005277223 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005806407 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077006335 Country of ref document: KR Ref document number: 980/KOLNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2005277223 Country of ref document: AU Date of ref document: 20050822 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005277223 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580034757.1 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005806407 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0514504 Country of ref document: BR |